ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Global evolution of ferroptosis research: a comprehensive bibliometric analysis of publication trends, geographic patterns, pharmacological innovation, and translational progress from inception through 2025.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mapping the global landscape of research on immune checkpoint inhibitor-associated cardiotoxicity: A quantitative and visualized bibliometric study (2016-2025).Human vaccines & immunotherapeutics · 2026Article
- Global Research Trends in Dietary Polyphenols for Preventing Non-Communicable Chronic Diseases: A Bibliometric Study.Food science & nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ferroptosis is an iron-dependent form of regulated cell death with increasing relevance to pharmacology, particularly in cancer therapy, neuroprotection, and metabolic disease modulation. Despite the rapid growth of the field, existing bibliometric studies remain fragmented, disease-specific, and largely confined to Web of Science databases, with limited coverage beyond 2023. This study presents a comprehensive dual-dataset Scopus-based bibliometric analysis of ferroptosis research (2012-2025), comprising 12,846 original articles representing the global landscape and 1797 pharmacologically enriched articles focused on therapeutic development. Using Bibliometrix, VOSviewer, and CiteSpace, the analysis evaluates publication trends, geographic distribution, collaboration networks, keyword co-occurrence, thematic evolution, and strategic mapping based on Bradford's Law and Callon's density-centrality metrics, characterizing publication dynamics, intellectual structure, translational trajectories, and pharmacological innovation patterns relevant to drug discovery. Results revealed exponential growth in output, particularly after 2020, with China contributing the largest share of publications, while Western countries demonstrated higher citation impact. Core mechanistic themes centered on GPX4, oxidative stress, and lipid peroxidation, whereas recent thematic evolution highlights increasing emphasis on immunotherapy, prognostic biomarkers, and non-oncological degenerative diseases. Pharmacological thematic mapping identified doxorubicin cardiotoxicity as a dominant motor theme, with sorafenib, network pharmacology, and ubiquitination emerging as foundational therapeutic constructs. This analysis positions ferroptosis as a mature and rapidly expanding pharmacological research domain, identifies key translational frontiers, and provides a strategic framework to guide future drug discovery and therapeutic development.
Indexed as
Identifiers
41569313What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.